PharmaCyte Biotech Inc
NASDAQ:PMCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Anyang Iron and Steel Co Ltd
SSE:600569
|
CN |
|
Xos Inc
NASDAQ:XOS
|
US |
|
S
|
Safari Industries (India) Ltd
NSE:SAFARI
|
IN |
|
Q
|
QNB Corp
OTC:QNBC
|
US |
|
V
|
Viet Nam Ocean Shipping JSC
VN:VOS
|
VN |
PharmaCyte Biotech Inc
Goodwill
PharmaCyte Biotech Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaCyte Biotech Inc
NASDAQ:PMCB
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Goodwill
$35.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Goodwill
$8.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
22%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Goodwill
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Goodwill
$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PharmaCyte Biotech Inc
Glance View
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Laguna Hills, California and currently employs 4 full-time employees. The company went IPO on 2003-09-11. The firm is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The firm's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. The company also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The firm is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.
